from heartwire

HYPERTENSION

FDA approves another triple-drug combination for resistant hypertension: Tribenzor

JULY 26, 2010 | Shelley Wood

Parsippany, NJ - The FDA has granted marketing approval to another three-drug combination for the treatment of hypertension in patients unable to get their blood pressure controlled with any two of the three classes of drugs that make up the combination [1]. The new product, Tribenzor (Daiichi Sankyo), combines the angiotensin-receptor blocker olmesartan (40 mg), the calcium-channel blocker amlodipine (10 mg), and the diuretic hydrochlorothiazide (HCTZ) (25 mg).

read more here